BAYU HEALTHCARE PVT. LTD. | Towards Prosperity
Rx Only — For Medical Professionals
BRAND SPOTLIGHT
Nezpray Family — Specialized Nasal Care
Evidence-Based Prescribing Guide for Clinicians | April 2026
NEZPRAY F™
Fluticasone Furoate Nasal Spray
27.5 mcg/spray
12 mL
120 Doses
Once Daily
NEZPRAY FA+™
Azelastine HCl + Fluticasone Propionate
Dual-Ingredient
7 gm
70 Doses
Twice Daily
1
Product Overview
2989
FF Receptor Affinity (RBA)
<0.5%
Nezpray F Systemic Bioavailability
15 min
Azelastine Onset of Action
2-in-1
Nezpray FA+ Mechanisms
≥2 yrs
Nezpray F Approved Age
8 hrs
Onset After First Dose (FF)
NEZPRAY F — Fluticasone Furoate 27.5 mcg
| Class | Intranasal Corticosteroid (INCS) — 3rd Generation Enhanced-Affinity |
| Strength | 27.5 mcg per metered spray |
| Volume / Doses | 12 mL / 120 metered doses |
| Dosing | Once Daily (OD) |
| Age | ≥2 years |
| Schedule | Rx — Schedule H |
| Key Benefit | Highest GR affinity + ocular symptom coverage + <0.5% bioavailability |
NEZPRAY FA+ — Azelastine HCl + Fluticasone Propionate
| Class | Fixed-Dose INCS + INAH (Intranasal Antihistamine) Combination |
| Composition | Azelastine HCl + Fluticasone Propionate |
| Volume / Doses | 7 gm / 70 metered doses |
| Dosing | Twice Daily (BID) |
| Age | ≥12 years |
| Schedule | Rx — Schedule H |
| Key Benefit | Dual early + late phase control; superior to either monotherapy alone |
2
Molecule Profiles — The Science Behind the Sprays
2A. Fluticasone Furoate (FF) — Active in Nezpray F
A third-generation enhanced-affinity synthetic glucocorticoid with the highest receptor binding affinity of any marketed intranasal corticosteroid. Derived from cortisol, FF provides exceptional local anti-inflammatory activity with negligible systemic exposure.
| Pharmacokinetic Parameter | Detail |
|---|---|
| GR Binding Affinity (RBA) | 2989 — Highest of any marketed intranasal corticosteroid (~2× fluticasone propionate) |
| Systemic Bioavailability | <0.5% — negligible; extensive hepatic first-pass metabolism via CYP3A4 |
| Protein Binding | >99% plasma protein bound (primarily albumin) |
| Volume of Distribution | 661 L — extensive tissue distribution; high lipophilicity |
| GR Receptor Residence Time | ~10.5 hours — the longest of any intranasal steroid (vs. FP ~7.8 hrs, budesonide ~5 hrs) |
| Onset of Action (nasal) | 8 hours after first dose — fastest among intranasal corticosteroids |
| Elimination | Primarily fecal (>90%); minimal urinary excretion |
| Metabolism | Extensive CYP3A4 first-pass hepatic metabolism; swallowed fraction fully inactivated |
| Molecular Advantage | Half the quantity needed to occupy same GR receptors as fluticasone propionate |
2B. Azelastine HCl — The Antihistamine in Nezpray FA+
A potent second-generation intranasal H1-receptor antagonist with a 15-minute onset of action. Uniquely effective against nasal congestion — a symptom typically unresponsive to oral antihistamines. Multi-modal anti-inflammatory beyond pure antihistamine action.
| Parameter | Detail |
|---|---|
| Onset of Action | As fast as 15 minutes — among the most rapid of any rhinitis medication |
| Class | Phthalazinone-class 2nd-generation intranasal H1-antihistamine |
| Mechanism | Selective H1-receptor blockade + mast-cell stabilization + inhibition of LTC4, PAF, IL-6, TNF-α, substance P, bradykinin |
| Anti-Congestion | Effective vs. nasal congestion (unlike most oral antihistamines) via direct mucosal vasoconstriction |
| Intranasal Bioavailability | ~40% — acts directly at the site of action |
| Duration of Action | ~12 hours — BID dosing provides round-the-clock control |
| Sedation Risk | Minimal with intranasal route; far less sedating than 1st-generation antihistamines |
| Notable Side Effect | Bitter taste if device tilted incorrectly — minimized with proper administration technique |
2C. Fluticasone Propionate (FP) — Corticosteroid Backbone in Nezpray FA+
| Parameter | Detail |
|---|---|
| GR Affinity (RBA) | 1800 — high potency with well-established clinical track record |
| Systemic Bioavailability | <2% — minimal systemic exposure |
| Mechanism | Broad transcriptional suppression of inflammatory genes; inhibits eosinophils, mast cells, T-lymphocytes, macrophages |
| Phase Covered | Late-phase allergic response (2–12+ hours after allergen exposure) |
| Synergy with Azelastine | Azelastine covers early-phase; FP covers late-phase → comprehensive dual-phase blockade |
| Protein Binding | ~91% |
| Volume of Distribution | 4.2 L/kg |
3
Mechanism of Action
3A. Nezpray F — How Fluticasone Furoate Works
FF binds with ultra-high affinity to glucocorticoid receptors (GR) in nasal mucosal cells. The FF–GR complex translocates to the nucleus and exerts dual genomic actions:
Transactivation — Anti-inflammatory Genes ON
- → Induces lipocortin-1 → inhibits phospholipase A2
- → Suppresses downstream eicosanoid synthesis
- → Reduces mucus production and vascular permeability
Transrepression — Pro-inflammatory Genes OFF
- → Suppresses NF-κB and AP-1 transcription factors
- → Reduces IL-4, IL-5, IL-13, chemokines, VCAM-1
- → Depletes nasal mucosal eosinophils, mast cells, T-cells
Comprehensive Coverage — All 4 Cardinal Symptoms + Ocular
Relieves rhinorrhea, sneezing, nasal itch, and nasal congestion. Uniquely documented to reduce ocular symptoms (itching, tearing, redness) — likely via naso-lacrimal reflex inhibition. Covers both early and late-phase allergic responses.
3B. Nezpray FA+ — Dual-Pathway Blockade (The Full Story)
EARLY PHASE (0–60 min)
Azelastine HCl
Blocks H1 receptors within 15 minutes. Prevents mast-cell mediator effects: immediate sneezing, rhinorrhea, itch, mucosal edema. Also inhibits LTC4, PAF, and cytokine release at the nasal mucosa.
+
LATE PHASE (2–12+ hrs)
Fluticasone Propionate
Suppresses eosinophil and T-cell infiltration, controls cytokine cascade (IL-4, IL-5, IL-13) and VCAM-1. Manages persistent nasal congestion and mucosal hyper-reactivity throughout the day.
Combined Result: Comprehensive Dual-Phase Control
Neither monotherapy alone achieves this breadth of coverage. The fixed-dose combination provides rapid, sustained, multi-mediator nasal symptom control across the full 24-hour allergen exposure cycle — as confirmed by multiple RCTs and meta-analyses.
4
Approved Indications & Clinical Use
NEZPRAY F — Indications
- Seasonal Allergic Rhinitis (SAR)All nasal + ocular symptom domains
- Perennial Allergic Rhinitis (PAR)Year-round allergen exposure
- Non-Allergic (Vasomotor) RhinitisPrescription formulation
- Nasal Symptoms in AsthmaUnited Airway Disease approach
- Ocular Symptoms of ARDocumented benefit vs. other INCS
- Nasal Polyposis (Adjunct)Off-label / specialist guidance
Dosing by Age
Adults & Adolescents ≥12 yrs: 2 sprays/nostril OD (110 mcg/day)
Children 2–11 yrs: 1 spray/nostril OD (55 mcg/day); can increase if needed
NEZPRAY FA+ — Indications
- Moderate-to-Severe SAR (Step-Up)When INCS alone is insufficient
- Moderate-to-Severe PARYear-round uncontrolled symptoms
- AR Uncontrolled on INCS MonotherapyARIA 2024–25 conditional recommendation
- AR with Prominent Ocular SymptomsDual-mechanism coverage
- AR Comorbid with AsthmaComprehensive nasal control
- Early-Morning Nasal BreakthroughRapid azelastine onset covers night-to-morning gap
Dosing by Age
Adults & Adolescents ≥12 yrs: 1 spray/nostril BID (morning + evening)
Children <12 yrs: Not routinely recommended — use Nezpray F
5
Dosing Guide
Nezpray F — Dosing (Fluticasone Furoate 27.5 mcg/spray)
| Patient Group | Initial Dose | Maintenance | Notes |
|---|---|---|---|
| Adults & Adolescents ≥12 yrs | 2 sprays/nostril OD (110 mcg/day) | 1 spray/nostril OD once controlled | Morning preferred for best 24-hr coverage |
| Children 2–11 yrs | 1 spray/nostril OD (55 mcg/day) | Can increase to 2 sprays if inadequate | Monitor growth if prolonged use (>1 yr) |
| Elderly | As per adult dosing | No dose adjustment required | Low systemic exposure — safe in elderly |
| Severe Hepatic Impairment | Use with caution | May increase FF exposure | Monitor for any systemic steroid effects |
| Pregnancy / Lactation | Consult specialist | <0.5% bioavailability — lowest systemic risk INCS | Benefits vs. risk; INCS generally low-risk |
Nezpray FA+ — Dosing (Azelastine HCl + Fluticasone Propionate)
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults & Adolescents ≥12 yrs | 1 spray/nostril | Twice daily — morning + evening | Shake gently before each use |
| Elderly | 1 spray/nostril BID | No adjustment needed | Monitor for rare mild CNS effects |
| Children <12 yrs | Not routinely recommended | Insufficient pediatric FA+ data | Use Nezpray F in children <12 yrs |
| Pregnancy | Consult specialist | Benefits vs. risk assessment | Both components have low systemic absorption |
Device Counseling Tips — Tell Your Patients
- ▸ Prime the pump before first use (5–6 actuations until a fine mist appears)
- ▸ Hold bottle upright; tilt head slightly forward — do NOT tilt device downward (causes bitter taste with azelastine)
- ▸ Insert nozzle into one nostril, close the other, breathe gently through the nose during actuation
- ▸ Breathe out through the mouth after spraying
- ▸ Wipe the nozzle clean after each use and replace the cap
6
Key Clinical Evidence & Studies
6A. Nezpray F — Fluticasone Furoate Clinical Evidence
1
Phase III Dose-Ranging Study — Seasonal Allergic Rhinitis
- Fluticasone furoate 110 mcg OD significantly improved rTNSS vs. placebo (p < 0.001 for all active doses)
- Onset of action: 8 hours after the very first dose — demonstrated at 110 mcg and 440 mcg groups
- Also significantly improved Total Ocular Symptom Score (TOSS) — itching, tearing, redness
- Safety: No HPA axis suppression; 24-hour urinary cortisol unchanged from placebo
- 110 mcg OD selected as optimal dose — best efficacy/safety ratio for Phase III
Reference: Martin BG, et al. Allergy Asthma Proc. 2007;28:216–225.
2
Perennial Allergic Rhinitis (PAR) — Adults & Adolescents
- FF 110 mcg OD produced significantly greater rTNSS reductions than placebo (primary endpoint; p < 0.001)
- Improvements across all 4 nasal symptom domains: congestion, rhinorrhea, sneezing, nasal itching
- Ocular symptom relief documented in PAR patients
- No clinically significant mucosal atrophy observed on nasal biopsy
- Adverse events: similar to placebo — confirmed excellent local safety
Reference: Kaiser HB et al. Ann Allergy Asthma Immunol. 2008.
3
Histological Evidence — Pre-treatment Mucosal Effect
- Significant histologic changes in nasal mucosa after just 4 weeks of fluticasone treatment
- Reductions in: Langerhans cells, mast cells, T-lymphocytes, macrophages, and eosinophils
- Cellular influx after allergen challenge significantly reduced in the fluticasone group
- Demonstrated effectiveness in BOTH early-phase AND late-phase allergic response
- Clinical implication: Pre-season initiation of Nezpray F (2–4 weeks before pollen season) significantly reduces mucosal allergic burden
Reference: StatPearls NIH, Updated May 2024 | DOI: 10.1067/mai.2002.120554
6B. Nezpray FA+ — Azelastine + Fluticasone Clinical Evidence
1
Landmark Phase III — AzeFlu vs. Monotherapy in SAR
- Combination AzeFlu spray provided statistically significant improvement in TNSS vs. azelastine alone (p < 0.001)
- Combination AzeFlu spray provided statistically significant improvement vs. fluticasone alone (p < 0.001)
- Additive clinical benefit confirmed — neither monotherapy alone achieved equivalent control
- Well tolerated; no new safety signals with the fixed-dose combination
- 4 arms: (1) Azelastine only, (2) Fluticasone only, (3) AzeFlu combination, (4) Placebo
Reference: Double-blind, placebo-controlled study — PubMed PMID: 20674829
2
Meta-Analysis — Superiority of AzeFlu (8 RCTs, PRISMA-Compliant)
- vs. Placebo: ΔTNSS −2.41 (95% CI −2.82 to −1.99; p < 0.001; I² = 60%)
- vs. Azelastine alone: ΔTNSS −1.40 (95% CI −1.82 to −0.98; p < 0.001; I² = 0%)
- vs. Fluticasone alone: ΔTNSS −0.74 (95% CI −1.17 to −0.31; p < 0.001; I² = 12%)
- All 8 studies showed greater decrease in symptom scores with combination vs. monotherapy
- Conclusion: AzeFlu is consistently and statistically superior to either monotherapy — combination should be second-line when monotherapy fails
Reference: PubMed PMID: 30961435 — Intranasal Azelastine and Fluticasone as Combination Therapy (Laryngoscope)
3
2025 RCT — Nasal Saline + AzeFlu vs. AzeFlu Alone
- Both groups showed significant TNSS reductions from baseline (p < 0.001)
- Saline irrigation + AzeFlu group showed greater LS-mean TNSS changes than AzeFlu alone at 2 weeks AND 4 weeks (p < 0.001 for both)
- RQLQ (quality of life) and rhinoscopic scores significantly better in the combination group
- Clinical implication: Adding nasal saline irrigation to Nezpray FA+ may further optimize outcomes in moderate-to-severe PAR
Reference: Frontiers in Allergy. Published September 2025. DOI: 10.3389/falgy.2025.1622510
4
2025 Systematic Review — AzeFlu in Pediatric & Adult AR
- AzeFlu provides faster AND greater symptom relief vs. fluticasone propionate monotherapy in children with AR
- Dual antihistaminic + anti-inflammatory mechanism provides broader symptom coverage
- Persistent AR associated with exacerbation of asthma, sinusitis, otitis media, nasal polyposis
- AzeFlu step-up reduces overall disease burden in patients with moderate-to-severe AR
Reference: Pharmaceuticals 2025, 18(11), 1624. DOI: 10.3390/ph18111624
7
Position in Current Guidelines — AR & Asthma Therapy
7A. ARIA 2024–2025 Guidelines (EAACI-Endorsed — Latest Update, December 2025)
The ARIA 2024–2025 guidelines (published December 2025), endorsed by EAACI and developed using the GRADE evidence-to-decision framework, represent the most current global guidance for allergic rhinitis pharmacotherapy.
ARIA 2024–2025: Key Recommendations on Intranasal Treatments
Rec. 1 — INCS
FIRST-LINE for Moderate-to-Severe AR. Intranasal corticosteroids are recommended as first-line pharmacotherapy. INCS are superior to oral antihistamines for nasal symptom control. → Nezpray F position: First-line therapy.
Rec. 2 — INAH+INCS
CONDITIONALLY RECOMMENDED over INCS alone or INAH alone. The ARIA 2024–2025 panel upgraded to a conditional recommendation in favor of fixed INAH+INCS combinations — a significant shift from prior guidelines. → Nezpray FA+ position: Evidence-based step-up.
Rec. 3 — INCS > INAH
When choosing between monotherapies, INCS is recommended over intranasal antihistamine alone. Intranasal treatments are also superior to oral medications for both nasal and ocular symptoms and quality of life.
7B. ARIA 2024–2025 Treatment Ladder
Mild Intermittent AR
Oral antihistamine or INCS monotherapyStep 1
Nezpray F (1–2 sprays/nostril OD) — first-line INCS choice
Nezpray F (1–2 sprays/nostril OD) — first-line INCS choice
Mild–Moderate Persistent AR
INCS — Nezpray F preferred first choiceStep 2
If inadequate response: escalate to Nezpray FA+ (INAH+INCS)
If inadequate response: escalate to Nezpray FA+ (INAH+INCS)
Moderate–Severe Persistent AR
INAH+INCS combination conditionally recommended (ARIA 2024–25)Step-Up
→ Nezpray FA+ — the guideline-supported step-up option
→ Nezpray FA+ — the guideline-supported step-up option
AR + Prominent Ocular Symptoms
INCS with documented ocular coverage OR INAH+INCS
Nezpray F (FF has unique ocular benefit) OR Nezpray FA+ (dual coverage) — both appropriate
Nezpray F (FF has unique ocular benefit) OR Nezpray FA+ (dual coverage) — both appropriate
AR Uncontrolled on INCS
Switch to INAH+INCS fixed combination
→ Switch to Nezpray FA+ (ARIA 2024–25: conditional recommendation)
→ Switch to Nezpray FA+ (ARIA 2024–25: conditional recommendation)
8
Position in Asthma Therapy — The United Airway Disease Concept
United Airway Disease — Key Evidence
80–95% of patients with asthma have concurrent allergic rhinitis — rhinitis is nearly universal in asthma patients.
Severe rhinitis in asthma is directly associated with worse asthma outcomes — more exacerbations, more emergency visits, more hospitalizations.
AR is an independent risk factor for asthma development in non-asthmatic individuals.
Treating nasal inflammation with INCS has been shown to reduce bronchial hyper-responsiveness and lower asthma-related emergency department visits.
| Asthma + AR Clinical Scenario | Recommended Nezpray Strategy |
|---|---|
| Asthma + AR (mild rhinitis) | Nezpray F OD — controls rhinitis, reduces airway hyper-responsiveness, lowers asthma exacerbation risk. Negligible systemic steroid load (<0.5% bioavailability) — safe even on inhaled ICS |
| Asthma + AR (moderate–severe rhinitis) | Nezpray FA+ BID — dual-mechanism control; comprehensive nasal management reduces asthma trigger burden. ARIA supports INAH+INCS step-up in uncontrolled AR |
| Asthma + AR + Ocular Symptoms | Nezpray F (FF documented ocular benefit) OR Nezpray FA+ — both appropriate; choose based on rhinitis severity |
| Pre-season prophylaxis in asthmatic patients | Start Nezpray F 2–4 weeks before allergen season — histological evidence of pretreatment mucosal benefit (reduced cellular infiltration) |
| Asthmatic patient on inhaled/oral ICS | Nezpray F preferred — <0.5% systemic bioavailability avoids additive systemic steroid burden vs. other INCS |
| Asthma + AR uncontrolled on INCS alone | Escalate to Nezpray FA+ — ARIA 2024–25 conditional recommendation for INAH+INCS step-up |
9
Safety & Tolerability Profile
NEZPRAY F — Safety
Common (>1%)Epistaxis (4–8%), nasal irritation/burning, headache, nasal dryness
Rare (<1%)Nasal septal perforation (very rare), Candida nasal infection, mild HPA changes at very high doses
Not observed in clinical trialsNo mucosal atrophy on biopsy; no growth inhibition at approved doses; no cortisol suppression; no cataract/glaucoma risk
HPA Axis — SafeNo HPA suppression at 110 mcg OD dose; 24-hr urinary cortisol unchanged from placebo in trials
Why it matters in children
Approved from age 2 years. No growth effects at approved doses in clinical trials, though 6-monthly height monitoring recommended for prolonged use (stadiometer).
NEZPRAY FA+ — Safety
Common (>1%)Bitter/unpleasant taste (dysgeusia) — 19/1000 patients; minimized with correct technique. Epistaxis rate similar to INCS alone (17/1000 vs. 18/1000)
Uncommon/RareSomnolence (rare with intranasal route), local nasal dryness, mild HPA considerations (same as INCS monotherapy)
vs. Monotherapy — No added riskEpistaxis rate NOT increased vs. INCS alone; No additive systemic steroid risk; No increased SAE risk vs. either monotherapy
Dysgeusia managementBitter taste minimized by correct upright device position. Counsel patients on technique at first prescription
Special Population Note
Not established below 12 years for FA+. For children 2–11 yrs, use Nezpray F (fluticasone furoate) which has established paediatric safety data.
Special Populations — Prescribing Notes
Pregnancy: INCS generally considered low risk. Nezpray F (<0.5% bioavailability) has the lowest systemic exposure of any INCS. Consult current guidelines.
Severe Hepatic Impairment: Fluticasone furoate exposure may increase — use Nezpray F with caution; monitor for systemic steroid effects.
Paediatrics: Nezpray F approved from age 2 yrs. Nezpray FA+ not established below 12 yrs. Monitor growth if prolonged INCS use.
Elderly: No dose adjustments for either product. Low systemic exposure of both sprays is advantageous in this population.
10
Nezpray F vs. Other Intranasal Corticosteroids — Where FF Stands Out
| Parameter | Fluticasone Furoate (Nezpray F) | Fluticasone Propionate | Mometasone Furoate | Budesonide |
|---|---|---|---|---|
| GR Binding Affinity (RBA) | 2989 — HIGHEST | 1800 | 2200 | 980 |
| Systemic Bioavailability | <0.5% — LOWEST | <2% | ~1% | ~34% (oral) |
| Onset of Action | 8 hrs (first dose) | 12–24 hrs | 12–24 hrs | 12–24 hrs |
| Ocular Symptom Coverage | YES — Documented | Partial | Less evidence | Limited data |
| Age Approved (nasal) | ≥2 years | ≥4 yrs (Rx) | ≥2 years | ≥6 years |
| GR Residence Time | ~10.5 hrs — LONGEST | ~7.8 hrs | Variable | ~5 hrs |
| Dosing Frequency | Once Daily | Once Daily | Once Daily | Once–Twice Daily |
| HPA Suppression Risk | Negligible at approved dose | Negligible | Negligible | Lower risk (intranasal) |
11
Key Messages for Prescribing Physicians
Why Prescribe Nezpray F?
1The Gold Standard INCS — Highest Receptor Affinity Available
Fluticasone furoate carries the highest GR binding affinity (RBA 2989) of any approved intranasal corticosteroid. This translates to maximum anti-inflammatory effect at minimal dose — giving patients 24-hour comprehensive nasal AND ocular symptom relief from a single once-daily spray.
2Fastest INCS Onset — Symptom Relief in 8 Hours After First Dose
Unlike most INCS that take 24–48 hours for initial effect, Nezpray F provides measurable symptom relief within 8 hours of the very first dose — improving early patient confidence in treatment and reducing dropout during the critical first week.
3Unmatched Systemic Safety — <0.5% Bioavailability
With systemic bioavailability below 0.5%, Nezpray F is among the safest intranasal steroids for prolonged use, including in children ≥2 years. No HPA axis suppression was observed in controlled clinical trials. Ideal for asthmatic patients already on inhaled or oral corticosteroids — avoids additive systemic steroid burden.
4Ocular Symptom Bonus — Beyond the Nose
Nezpray F uniquely provides documented relief from ocular symptoms (itching, tearing, redness). This often eliminates the need for additional antihistamine eye drops, reducing polypharmacy burden and improving patient convenience — a real-world prescribing advantage.
5Approved From Age 2 — Confidence Across All Age Groups
Regulatory approval from age 2 years provides dosing flexibility across your full patient spectrum — paediatric, adult, and elderly. A single trusted molecule for your entire practice population managing allergic rhinitis.
Why Prescribe Nezpray FA+?
1When INCS Alone Isn't Enough — The Guideline-Supported Step-Up
ARIA 2024–2025 (the latest global guideline, December 2025) now conditionally recommends INAH+INCS fixed combinations OVER INCS alone for AR. When your patient returns with inadequate relief on monotherapy, Nezpray FA+ is the evidence-based, guideline-supported next step.
2Faster Relief, Broader Control — Dual-Phase Mechanism
Azelastine acts within 15 minutes — before the steroid even begins working. Fluticasone propionate then provides sustained late-phase anti-inflammatory control for hours. The result: comprehensive relief across the full 24-hour allergen exposure cycle that neither agent achieves alone.
3Meta-Analysis Proven Superiority — 8 RCTs Confirm
Published systematic review and meta-analysis (8 RCTs, PRISMA-compliant) confirms AzeFlu combination is statistically and clinically superior to azelastine alone (ΔTNSS −1.40; p < 0.001) AND to fluticasone alone (ΔTNSS −0.74; p < 0.001). The evidence base is robust and unambiguous.
4Simplifies Adherence — One Bottle, Two Mechanisms
A fixed-dose combination in a single spray device eliminates the need for multiple nasal medications, improving patient convenience, reducing prescription complexity, and significantly improving adherence — which is a primary determinant of real-world efficacy in chronic AR.
5Ideal for Asthma Comorbidity — Protecting the Lower Airway
In asthmatic patients with uncontrolled rhinitis, Nezpray FA+ provides rapid + sustained dual-mechanism nasal control that reduces asthma trigger burden — aligning with the United Airway Disease model endorsed by ARIA and GINA. Treating the nose treats the lung.
Patient Selection Guide
Choose NEZPRAY F when…
First-line monotherapy
- First-line therapy in mild-to-moderate AR
- Patient is a child (2–11 years)
- Significant ocular symptoms (FF uniquely documented)
- Patient on multiple medications — simplify with once-daily
- On inhaled/systemic ICS for asthma — lowest bioavailability INCS
- Pre-season prophylaxis in pollen-allergic patients
- Non-allergic (vasomotor) rhinitis
Choose NEZPRAY FA+ when…
Step-up / moderate-severe AR
- Moderate-to-severe AR requiring step-up therapy
- Inadequate response to INCS monotherapy
- Rapid onset needed (azelastine — 15 min)
- Dominant sneezing, rhinorrhea, or itch phenotype
- AR comorbid with asthma — comprehensive nasal control
- Patient using multiple nasal sprays — simplify to one bottle
- ARIA 2024–25 INAH+INCS step-up recommendation applies
12
Quick Reference Summary
| Feature | Nezpray F | Nezpray FA+ | Clinical Takeaway |
|---|---|---|---|
| Active Ingredient(s) | Fluticasone Furoate 27.5 mcg/spray | Azelastine HCl + Fluticasone Propionate | Different mechanisms — different patient profiles |
| Volume / Doses | 12 mL / 120 doses | 7 gm / 70 doses | Nezpray F: more doses per bottle |
| Mechanism | INCS only — GR-mediated anti-inflammatory | INAH + INCS — dual early + late phase | FA+ for comprehensive dual-phase blockade |
| Onset of Action | 8 hours (fastest INCS) | 15 min (azelastine) + hours (FP) | FA+ better for acute symptom urgency |
| Dosing Frequency | Once Daily (OD) | Twice Daily (BID) | F: superior adherence; FA+: broader coverage |
| Age Approved | ≥2 years | ≥12 years | F for paediatrics; FA+ for adults/adolescents |
| Guideline Position (ARIA 2024–25) | First-line INCS | Step-up: INAH+INCS conditionally preferred | F first-line; FA+ when F is insufficient |
| Asthma Utility | High — reduces upstream airway inflammation | High — dual mechanism controls AR triggers | Both support United Airway Disease strategy |
| Ocular Coverage | YES — documented with FF | YES — via both agents | Both appropriate for AR with eye symptoms |
| Systemic Safety | <0.5% bioavailability — lowest of all INCS | No added SAE risk vs. monotherapy | Both have excellent local safety profiles |